{"title":"重度或极重度再生障碍性贫血患者对免疫抑制疗法的治疗反应及其预测因素","authors":"Thanakrit Somprasertkul , Weerayaporn Trirattanapikul , Sittichai Khamsai , Verajit Chotmongkol , Kittisak Sawanyawisuth","doi":"10.1016/j.medidd.2024.100181","DOIUrl":null,"url":null,"abstract":"<div><p>Severe aplastic anemia (SAA) is a hematological condition with high morbidity and mortality. Treatment with immunosuppressive agents is alternative treatment if bone marrow transplant is not available. Several studies reported predictors of successful treatment in patients with SAA. However, the results are not consistent and not specific to anti-thymocyte globulin and cyclosporine. This study aimed to evaluate the predictor of response to treatment in this specific regimen. This study was a retrospective cohort study. The inclusion criteria were adult patients with SAA or very SAA who received this regimen. Clinical factors predictive of response to treatment were computed. There were 92 patients met the study criteria. Of those, 56 patients (60.87%) were in a group of response to treatment. There were nine factors in the predictive model for good response to treatment. Only body mass index was independently associated with response to treatment with an adjusted odds ratio of 1.31 (95% confidence interval of 1.04, 1.67). Age or hematological laboratory factors such as lymphocyte or neutrophil count were not significant. Low body mass index may be less likely to response to immunosuppressive treatment in patients with severe or very severe aplastic anemia.</p></div>","PeriodicalId":33528,"journal":{"name":"Medicine in Drug Discovery","volume":"22 ","pages":"Article 100181"},"PeriodicalIF":0.0000,"publicationDate":"2024-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S259009862400006X/pdfft?md5=c7cc3102353ae4f94e197711f5758dd4&pid=1-s2.0-S259009862400006X-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Treatment response and its predictors of immunosuppressive therapy in patients with severe or very severe aplastic anemia\",\"authors\":\"Thanakrit Somprasertkul , Weerayaporn Trirattanapikul , Sittichai Khamsai , Verajit Chotmongkol , Kittisak Sawanyawisuth\",\"doi\":\"10.1016/j.medidd.2024.100181\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Severe aplastic anemia (SAA) is a hematological condition with high morbidity and mortality. Treatment with immunosuppressive agents is alternative treatment if bone marrow transplant is not available. Several studies reported predictors of successful treatment in patients with SAA. However, the results are not consistent and not specific to anti-thymocyte globulin and cyclosporine. This study aimed to evaluate the predictor of response to treatment in this specific regimen. This study was a retrospective cohort study. The inclusion criteria were adult patients with SAA or very SAA who received this regimen. Clinical factors predictive of response to treatment were computed. There were 92 patients met the study criteria. Of those, 56 patients (60.87%) were in a group of response to treatment. There were nine factors in the predictive model for good response to treatment. Only body mass index was independently associated with response to treatment with an adjusted odds ratio of 1.31 (95% confidence interval of 1.04, 1.67). Age or hematological laboratory factors such as lymphocyte or neutrophil count were not significant. Low body mass index may be less likely to response to immunosuppressive treatment in patients with severe or very severe aplastic anemia.</p></div>\",\"PeriodicalId\":33528,\"journal\":{\"name\":\"Medicine in Drug Discovery\",\"volume\":\"22 \",\"pages\":\"Article 100181\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S259009862400006X/pdfft?md5=c7cc3102353ae4f94e197711f5758dd4&pid=1-s2.0-S259009862400006X-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicine in Drug Discovery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S259009862400006X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicine in Drug Discovery","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S259009862400006X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
重型再生障碍性贫血(SAA)是一种发病率和死亡率都很高的血液病。在无法进行骨髓移植的情况下,使用免疫抑制剂是一种替代治疗方法。一些研究报告了再生障碍性贫血患者成功治疗的预测因素。然而,研究结果并不一致,也没有针对抗胸腺细胞球蛋白和环孢素的特异性研究。本研究旨在评估这种特殊疗法的治疗反应预测因素。本研究是一项回顾性队列研究。纳入标准为接受该疗法的 SAA 或极 SAA 成年患者。对预测治疗反应的临床因素进行了计算。共有 92 名患者符合研究标准。其中,56 名患者(60.87%)对治疗有反应。治疗反应良好的预测模型中有九个因素。只有体重指数与治疗反应独立相关,调整后的几率比为 1.31(95% 置信区间为 1.04,1.67)。年龄或血液实验室因素(如淋巴细胞或中性粒细胞计数)并不重要。体重指数低可能会降低重度或极重度再生障碍性贫血患者对免疫抑制治疗的反应。
Treatment response and its predictors of immunosuppressive therapy in patients with severe or very severe aplastic anemia
Severe aplastic anemia (SAA) is a hematological condition with high morbidity and mortality. Treatment with immunosuppressive agents is alternative treatment if bone marrow transplant is not available. Several studies reported predictors of successful treatment in patients with SAA. However, the results are not consistent and not specific to anti-thymocyte globulin and cyclosporine. This study aimed to evaluate the predictor of response to treatment in this specific regimen. This study was a retrospective cohort study. The inclusion criteria were adult patients with SAA or very SAA who received this regimen. Clinical factors predictive of response to treatment were computed. There were 92 patients met the study criteria. Of those, 56 patients (60.87%) were in a group of response to treatment. There were nine factors in the predictive model for good response to treatment. Only body mass index was independently associated with response to treatment with an adjusted odds ratio of 1.31 (95% confidence interval of 1.04, 1.67). Age or hematological laboratory factors such as lymphocyte or neutrophil count were not significant. Low body mass index may be less likely to response to immunosuppressive treatment in patients with severe or very severe aplastic anemia.